AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

10.600

+0.2802.71%

Volume:74.47K

Turnover:778.76K

Market Cap:532.13M

PE:16.47

High:10.610

Open:10.320

Low:10.260

Close:10.320

52wk High:13.933

52wk Low:8.350

Shares:50.20M

Float Shares:41.32M

Volume Ratio:0.47

T/O Rate:0.18%

Dividend:0.05

Dividend Rate:0.47%

EPS(TTM):0.644

EPS(LYR):0.718

ROE:13.96%

ROA:10.62%

PB:2.14

PE(LYR):14.76

Loading ...

Overview Company News Filings

Clinuvel Schedules Annual Results Investor Webinar

Clinuvel Plans Additional Preclinical Study of VLRX-L Controlled-Release Peptide Platform in Q1 2027

Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform

MT Newswires Live

Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market

MT Newswires Live

Clinuvel Benchmarks Vitiligo Market as JAK Inhibitor Efficacy Challenges Nb-uvb Standard of Care

Clinuvel Pharmaceuticals Plans to Report Late-Stage Vitiligo Study Topline Results in December

MT Newswires Live

Clinuvel Pharmaceuticals - Cuv105 Vitiligo Topline Results Expected in December 2026

THOMSON REUTERS

Press Release: Clinuvel Implements Strategic Reorganisation to Refocus on U.S. Markets

Clinuvel Shifts Corporate Headquarters to US Effective Jan. 1, 2027

Clinuvel Pharmaceuticals Announces Strategic Reorganisation to Refocus on U.S. Markets

Clinuvel Pharmaceuticals to Move Headquarters to US, Plan Workforce Reduction of Up to 20%

MT Newswires Live

Australian Shares Open Higher as Oil, Gold Rally on Middle East Tensions; Santos Posts Higher Q2 Total Production

MT Newswires Live

Clinuvel Pharmaceuticals - Restructuring to Enable Access to Deeper U.S. Capital Pools

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd-clinuvel Strategic Reorganisation to Refocus on U.S. Markets

THOMSON REUTERS

Clinuvel Pharmaceuticals - to Reduce Global Workforce by 10%-20% and Relocate Functions to U.S.

THOMSON REUTERS

Clinuvel Pharmaceuticals - to Relocate Corporate Headquarters to United States Effective 1 January 2027

THOMSON REUTERS

Clinuvel Pharmaceuticals - to Focus Operational Resources on U.S. Pharmaceutical Pipeline and Strategy

THOMSON REUTERS

Clinuvel Pharmaceuticals Confirms ADS Start Trading on Nasdaq

MT Newswires Live

Clinuvel’s Ads to Commence Trading on NASDAQ

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd's ADS to Commence Trading on NASDAQ

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":10.6,"timestamp":1787638320000,"preClose":10.32,"halted":0,"volume":74465,"delay":0,"changeRate":0.02713178294573637,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.643659,"marketStatus":"Not Yet Opened","change":0.28,"latestTime":"08-25 16:12:00 AEST","open":10.32,"high":10.61,"low":10.26,"amount":778757,"amplitude":0.033915,"askPrice":10.63,"askSize":114,"bidPrice":10.6,"bidSize":186,"shortable":3,"etf":0,"ttmEps":0.643659,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.32,"dividendRate":0.004717,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.470836,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":10.32,"auctionPrice":10.6,"auctionVolume":4812,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638203502}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"10.62%","roe":"13.96%","lyrEps":0.717999,"volumeRatio":0.470836,"shares":50200740,"dividePrice":0.05,"high":10.61,"amplitude":0.033915,"preClose":10.32,"low":10.26,"week52Low":8.35,"pbRate":"2.14","psRate":"5.53","week52High":13.933,"institutionHeld":0,"latestPrice":10.6,"committee":0.24,"eps":0.643659,"divideRate":0.004717,"volume":74465,"delay":0,"ttmEps":0.643659,"open":10.32,"prevYearClose":12.46,"prevWeekClose":10.42,"prevMonthClose":9.06,"prevQuarterClose":10.28,"fiveDayClose":10.36,"twentyDayClose":9.81,"sixtyDayClose":9.26,"earningDate":1787760000000,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660835962","title":"Clinuvel Schedules Annual Results Investor Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835962?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:08","pubTimestamp":1787220517,"startTime":"0","endTime":"0","summary":"Clinuvel schedules annual results investor webinarClinuvel schedules FY2026 results release for Aug. 27, 2026.Investor, analyst webinar set for Aug. 27, 2026, 18:00-18:30 AEST (10:00-10:30 CET).Regist","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL2slQHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976515","title":"Clinuvel Plans Additional Preclinical Study of VLRX-L Controlled-Release Peptide Platform in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976515?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:13","pubTimestamp":1786529595,"startTime":"0","endTime":"0","summary":"Clinuvel plans additional preclinical study of VLRX-L controlled-release peptide platform in Q1 2027Clinuvel updated on VLRX-L, a controlled-release liquid injectable peptide platform, following precl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLX8KKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658245944","title":"Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2658245944","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658245944?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:34","pubTimestamp":1786494881,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said it identified flexible liquid dose formulations that have shown the most potential for further development as part of its VLRX-L injectable peptide formulation ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655106845","title":"Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2655106845","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655106845?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:14","pubTimestamp":1785374061,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  strengthened its supply chain, scaled up its North American infrastructure, and engaged more than 100 potential new specialty centers as part of commercial preparations for the North American vitiligo market, according to a Thursday filing with the Australian bourse.The company is developing Scenesse as the first systemic, or total body, repigmentation therapy for vitiligo, a condition that causes the loss of skin color.Scenesse adopts a different approach to treatment by targeting melanocortin receptors to stimulate the natural body process that creates pigments to color human skin, unlike JAK inhibitor therapies that suppress the immune system, the company said.Extensive vitiligo, where more than 10% of the total body surface is affected by depigmentation, currently lacks an effective therapy, Clinuvel said, adding that prior studies of Scenesse in combination with the current standard of care showed significantly improved repigmentation compared to just sta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","AFG","BK4117","BK4107","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655845588","title":"Clinuvel Benchmarks Vitiligo Market as JAK Inhibitor Efficacy Challenges Nb-uvb Standard of Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2655845588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655845588?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:59","pubTimestamp":1785373191,"startTime":"0","endTime":"0","summary":"Clinuvel benchmarks vitiligo market as JAK inhibitor efficacy challenges NB-UVB standard of careClinuvel published a commercial update benchmarking the emerging vitiligo market against NB-UVB photothe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL37kpGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654960021","title":"Clinuvel Pharmaceuticals Plans to Report Late-Stage Vitiligo Study Topline Results in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2654960021","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654960021?lang=en_us&edition=fundamental","pubTime":"2026-07-28 08:38","pubTimestamp":1785199132,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  is completing its first late-stage study of Scenesse in vitiligo, a condition that causes the loss of skin color, and expects to report topline results in December, according to a Tuesday filing with the Australian bourse.The trial has enrolled 210 patients globally, and its primary endpoint focuses on the proportion of patients who achieve a total body surface area response of equal to or greater than 50%, per the filing.The late-stage trial will be followed by a registration study that is expected to start in November, with a 12-month recruitment period planned, the company said.Clinuvel shares gained 1% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654026464","title":"Clinuvel Pharmaceuticals - Cuv105 Vitiligo Topline Results Expected in December 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654026464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654026464?lang=en_us&edition=fundamental","pubTime":"2026-07-28 06:57","pubTimestamp":1785193028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T155:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653130607","title":"Press Release: Clinuvel Implements Strategic Reorganisation to Refocus on U.S. Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2653130607","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653130607?lang=en_us&edition=fundamental","pubTime":"2026-07-23 12:10","pubTimestamp":1784779800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and NEW YORK, July 23, 2026  -- CLINUVEL PHARMACEUTICALS LTD  today announced a strategic reorganisation of its operations and workforce, effective 1 January 2027, concurrent with the relocation of its corporate headquarters to the United States.\"We have long contemplated a U.S. listing and concluded that the Company has reached a stage of maturity sufficient to attract the attention of U.S. investors,\" said Mr Lachlan Hay, CLINUVEL's Chief Operating Officer. \"Based on feedback from recent non-deal roadshows, CLINUVEL's profile is seen as distinct from many U.S. biopharmaceuticals, while many U.S. investors expressed a preference to invest in U.S.-focused and listed companies. Since our future operations will be centred in the United States, we are now positioning the business functions for these next phases.\"Restructuring Highlights-- Headquarters Relocation: CLINUVEL's corporate headquarters and key. -- Workforce Reduction: the Company is reducing its global work","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","EPP","IEIH","LNGR","BK7067","BK4022","BK7508","BK4582","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653579040","title":"Clinuvel Shifts Corporate Headquarters to US Effective Jan. 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2653579040","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653579040?lang=en_us&edition=fundamental","pubTime":"2026-07-23 10:14","pubTimestamp":1784772899,"startTime":"0","endTime":"0","summary":"Clinuvel shifts corporate headquarters to US effective Jan. 1, 2027Clinuvel announced plans to relocate its corporate headquarters to the U.S., effective Jan. 1, 2027, alongside a strategic reorganiza","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL55cjNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653790370","title":"Clinuvel Pharmaceuticals Announces Strategic Reorganisation to Refocus on U.S. Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2653790370","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653790370?lang=en_us&edition=fundamental","pubTime":"2026-07-23 09:46","pubTimestamp":1784771167,"startTime":"0","endTime":"0","summary":"July 23 (Reuters) - Clinuvel Pharmaceuticals Ltd::*CLINUVEL STRATEGIC REORGANISATION TO REFOCUS ON U.S. MARKETS*TO RELOCATE CORPORATE HEADQUARTERS TO UNITED STATES EFFECTIVE 1 JANUARY 2027*TO REDUCE G","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nRSDbXvHFt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653792992","title":"Clinuvel Pharmaceuticals to Move Headquarters to US, Plan Workforce Reduction of Up to 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653792992","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653792992?lang=en_us&edition=fundamental","pubTime":"2026-07-23 08:40","pubTimestamp":1784767245,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said it will relocate its corporate headquarters to the US from Jan. 1, 2027, as the company restructures operations to support US market expansion and enhance access to capital, according to a Thursday Australian bourse filing.The company will reduce its global workforce by around 10% to 20% and redirect resources toward its US-focused pharmaceutical pipeline, with a particular emphasis on late-stage vitiligo programs, the filing said.The company said the move is driven by stronger US investor demand, deeper specialty pharmaceutical capital markets, and the potential for higher valuation multiples than Australian Securities Exchange-listed peers, the filing added.Clinuvel Pharmaceuticals' shares added 2% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653794403","title":"Australian Shares Open Higher as Oil, Gold Rally on Middle East Tensions; Santos Posts Higher Q2 Total Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2653794403","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653794403?lang=en_us&edition=fundamental","pubTime":"2026-07-23 08:17","pubTimestamp":1784765869,"startTime":"0","endTime":"0","summary":"Australian shares opened higher on Thursday as oil prices surged to their highest level in more than a month amid escalating US-Iran tensions and growing concerns over potential supply disruptions linked to threats against shipping routes.Gold prices also climbed to a two-week high on a softer US dollar and renewed safe-haven demand, while investors awaited fresh signals on the Federal Reserve's interest rate path.Overnight, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average fell 0.1%, 0.6%, and 0.01%, respectively.In the macroeconomy, Australia's labor force report is due at 11:30 am Sydney time.In corporate news, Santos  reported total production of 23.1 million barrels of oil equivalent  in the second quarter ended June 30, up on last year's 22.2 MMboe.Clinuvel Pharmaceuticals  said it will move its headquarters to the US from Jan. 1, 2027, as part of a restructuring that includes a 10% to 20% global workforce reduction and a shift toward US-focused operations, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IISV.AU","OZF.AU","XJO.AU","QFN.AU","TSS","IMLC.AU","XKO.AU","QRE.AU","DACE.AU","STO.AU","BEAR.AU","BK7507","BK7508","IIGF.AU","BK7142","GEAR.AU","VAP.AU","EIGA.AU","OZR.AU","E200.AU","SLF.AU","CUV.AU","IOZ.AU","GIVE.AU","ZYAU.AU","BK7067","BBOZ.AU","XAO.AU","VAS.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653912707","title":"Clinuvel Pharmaceuticals - Restructuring to Enable Access to Deeper U.S. Capital Pools","url":"https://stock-news.laohu8.com/highlight/detail?id=2653912707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653912707?lang=en_us&edition=fundamental","pubTime":"2026-07-23 07:11","pubTimestamp":1784761877,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUE2PDFF0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791279","title":"Clinuvel Pharmaceuticals Ltd-clinuvel Strategic Reorganisation to Refocus on U.S. Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653791279?lang=en_us&edition=fundamental","pubTime":"2026-07-23 07:11","pubTimestamp":1784761877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUE2PDFF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791277","title":"Clinuvel Pharmaceuticals - to Reduce Global Workforce by 10%-20% and Relocate Functions to U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653791277?lang=en_us&edition=fundamental","pubTime":"2026-07-23 07:11","pubTimestamp":1784761877,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUE2PDFF0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791272","title":"Clinuvel Pharmaceuticals - to Relocate Corporate Headquarters to United States Effective 1 January 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653791272?lang=en_us&edition=fundamental","pubTime":"2026-07-23 07:11","pubTimestamp":1784761877,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUE2PDFF0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271791","title":"Clinuvel Pharmaceuticals - to Focus Operational Resources on U.S. Pharmaceutical Pipeline and Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271791?lang=en_us&edition=fundamental","pubTime":"2026-07-23 07:11","pubTimestamp":1784761877,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUE2PDFF0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653241291","title":"Clinuvel Pharmaceuticals Confirms ADS Start Trading on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2653241291","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653241291?lang=en_us&edition=fundamental","pubTime":"2026-07-21 07:40","pubTimestamp":1784590854,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  confirmed that its American Depositary Share  began trading on the Nasdaq Stock Market on Monday under the ticker symbol \"CUVL,\" according to a Tuesday Australian bourse filing.This completed the uplift of the firm's previous American Depositary Receipt, \"CLVLY,\" from Level I to Level II.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LCLG","BK7067","CUV.AU","NQmain","ADS.AU","BK7016","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652262170","title":"Clinuvel’s Ads to Commence Trading on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2652262170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652262170?lang=en_us&edition=fundamental","pubTime":"2026-07-20 13:37","pubTimestamp":1784525851,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA5PFX6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652265796","title":"Clinuvel Pharmaceuticals Ltd's ADS to Commence Trading on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2652265796","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652265796?lang=en_us&edition=fundamental","pubTime":"2026-07-20 09:33","pubTimestamp":1784511208,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On NasdaqJuly 20 (Reuters)-Clinuvel Pharmaceuticals LtdCUV.AX:CLINUVEL'S ADS TO COMMENCE TRADING ON NASDAQADS EXPECTED TO COMMENCE TRADING ON NASDAQ UNDER TICKER CUVL ON JULY 20Further company coverage:CUV.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUE5CT7GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}